Newsletter

Blog

Contact Us

News

Subscribe to Vivoblog

Top-3 OCT Skin-Imaging publication topics in 2023

Optical Coherence Tomography, OCT, is being widely adopted for clinical, research and commercial skin-imaging applications As the leading dermatological OCT system VivoSight Dx has completed over 200,000 patient scans and has been used in over 500 peer-reviewed publications worldwide. During 2023 a total of 69 new peer-reviewed publications appeared featuring OCT imaging performed with VivoSight ...
Vivosight OCT Skin Imaging publications in 2023

Dermatological Optical Coherence Tomography (OCT) imaging available in Korea

Michelson Diagnostics is delighted to announce that it has received Korean Ministry of Food and Drug Safety, MFDS, (formerly the KFDA) approval for the VivoSight Dx Optical Coherence Tomography (OCT) system.  VivoSight Dx is globally the most widely used OCT system for dermatological imaging, providing high-resolution, non-invasive images through the skin for a wide spectrum ...
KFDA approval image 2

Study finds Dynamic OCT can distinguish nevi and melanomas based on blood vessel morphology

The study, published in Cancers clinical journal, showed that VivoSight’s powerful Dynamic OCT (D-OCT) capability for detecting and imaging blood vessels in skin has the potential to help dermatologists non-invasively distinguish melanomas from suspicious nevi in unclear cases. According to the paper authors, adding D-OCT imaging to clinic-dermoscopic examination may: In the study, D-OCT images ...
News_Image1

New Hope for Port Wine Stain Patients from a Novel Image-Guided Treatment

“We are enthusiastic about the results we are seeing with our VivoSight OCT-guided treatments of Port Wine Stain birthmarks”, said Dr Roy Geronemus of the Laser & Skin Surgery Center of New York, and who has been testing the VivoSight OCT system, “This new technology has great potential to change therapies for vascular conditions. The ...
News_Image5